C Katlama

Summary

Country: France

Publications

  1. ncbi TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results
    C Katlama
    Hopital Pitie Salpetriere, Paris, France
    HIV Med 4:79-86. 2003
  2. ncbi Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
  3. ncbi Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
    Christine Katlama
    Hopital Pitie Salpetriere, Paris, France
    AIDS 21:395-402. 2007
  4. ncbi MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
    C Katlama
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 2:20-6. 2001
  5. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
  6. ncbi Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
    B Autran
    Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
    Science 277:112-6. 1997
  7. ncbi Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
    Julie Bertrand
    UMR 738, INSERM, Universite Paris Diderot, UFR de Medecine, 16, rue Henri Huchard, 75018, Paris, France
    Eur J Clin Pharmacol 65:667-78. 2009
  8. ncbi Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    Y Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 30:1302-6. 1999
  9. ncbi Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure
    C Delaugerre
    Department of Virology, , Paris, France
    AIDS 15:2189-91. 2001
  10. ncbi Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial
    M A Valantin
    Department of Clinical Infectious and Tropical Diseases, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:625-35. 2008

Detail Information

Publications128 found, 100 shown here

  1. ncbi TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results
    C Katlama
    Hopital Pitie Salpetriere, Paris, France
    HIV Med 4:79-86. 2003
    ..To assess the antiviral efficacy, safety, and adherence in subjects who switched to Trizivir following long-term HIV-1 RNA suppression...
  2. ncbi Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
    ..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
  3. ncbi Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
    Christine Katlama
    Hopital Pitie Salpetriere, Paris, France
    AIDS 21:395-402. 2007
    ..The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients...
  4. ncbi MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
    C Katlama
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 2:20-6. 2001
    ..Since eradication of HIV is unlikely, long-term management of the disease necessitates careful evaluation of the combinations of currently available drugs to determine the most potent and useful rational sequencing of regimens...
  5. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  6. ncbi Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
    B Autran
    Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
    Science 277:112-6. 1997
    ..Thus, decreasing the HIV load can reverse HIV-driven activation and CD4(+) T cell defects in advanced HIV-infected patients...
  7. ncbi Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
    Julie Bertrand
    UMR 738, INSERM, Universite Paris Diderot, UFR de Medecine, 16, rue Henri Huchard, 75018, Paris, France
    Eur J Clin Pharmacol 65:667-78. 2009
    ..To assess the relationship between genetic polymorphisms and indinavir pharmacokinetic variability and to study the link between concentrations and short-term response or metabolic safety...
  8. ncbi Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    Y Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 30:1302-6. 1999
    ..Lamivudine (300 mg/d) is effective for the inhibition of HBV replication in HIV-infected patients. However, emergence of lamivudine-resistant HBV may occur in 20% of patients per year...
  9. ncbi Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure
    C Delaugerre
    Department of Virology, , Paris, France
    AIDS 15:2189-91. 2001
    ..The outgrowth of residual wild-type virus seems not to be a true genetic reversion because drug mutations are detected rapidly at salvage therapy re-initiation...
  10. ncbi Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial
    M A Valantin
    Department of Clinical Infectious and Tropical Diseases, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:625-35. 2008
    ..To evaluate the impact on peripheral fat tissue of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen in lipoatrophic HIV-1 infected patients...
  11. ncbi Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study
    H Ait-Mohand
    Service de Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    HIV Med 9:738-46. 2008
    ..Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries. This study's aim was to determine the efficacy and safety profile of lower-dose d4T...
  12. ncbi Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière and UPRES A 8067, Paris, France
    Hepatology 30:1054-8. 1999
    ..HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate...
  13. ncbi Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
    G Gorochov
    Laboratoire d Immunologie Cellulaire, CERVI, URA CNRS 625, Hopital Pitie Salpetriere, Paris, France
    Nat Med 4:215-21. 1998
    ..These results indicate that, besides CD4+ cell count rise, an efficient control of HIV replication may allow qualitative modifications of the CD4+ repertoire balance...
  14. ncbi Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
    V Thibault
    Laboratoire de Virologie, Service d Hepato gastro enterologie, Service des Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, 75013 Paris, France
    J Clin Microbiol 37:3013-6. 1999
    ..This study demonstrates the emergence of particular genetic profiles in HBV-HIV-coinfected patients experiencing a loss of control of HBV infection despite high doses of lamivudine...
  15. ncbi Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy
    M Mouroux
    Department of Virology, , Paris, France
    Antivir Ther 6:179-83. 2001
    ..One hypothesis explaining these results could be the development of the M184V mutation...
  16. ncbi Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
    W Rozenbaum
    Maladies Infectieuses Trĵpicales, Hĵpital Rothschild, Paris, France
    Antivir Ther 6:135-42. 2001
    ..To evaluate the safety and antiretroviral activity of intensification with abacavir in patients treated with lamivudine/zidovudine for > or = 12 weeks...
  17. ncbi Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
    AIDS 22:1203-11. 2008
    ..To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer...
  18. ncbi [Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals]
    A Schnuriger
    Service de Virologie, , 83, , 75651 Paris Cedex 13, France
    Pathol Biol (Paris) 54:578-86. 2006
    ..However, in case of clinical acute hepatitis C, sensitive HCV-RNA detection should remain the gold standard...
  19. ncbi Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
    I Kousignian
    INSERM U, Paris, France
    J Antimicrob Chemother 65:138-44. 2010
    ....
  20. ncbi Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy
    C Katlama
    Pitie-Salpetriere Hospital, Paris, France
    AIDS 17:1855-6. 2003
    ..Switch maintenance may be an appropriate strategy in patients treated with an NNRTI...
  21. ncbi Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 23:817-24. 2009
    ..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial...
  22. ncbi Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study
    R Landman
    Bichat Claude Bernard Hospital, Paris, France
    HIV Clin Trials 6:291-301. 2005
    ..To assess the efficacy and safety of the triple NRTI combination of abacavir (ABC), lamivudine (3TC), and tenofovir (TDF) in a once-daily regimen...
  23. ncbi Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial
    C Katlama
    , Paris, France
    HIV Med 2:27-34. 2001
    ..The presence of M184V at baseline had minimal impact on the efficacy of ABC...
  24. ncbi Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 36:2143-5. 1998
    ..LiPA is suitable for detecting mixed populations and easy to implement in clinical laboratories and might be useful for epidemiological surveys of primary HIV-1 resistance...
  25. ncbi Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Lancet 358:718-23. 2001
    ..We assessed the safety and efficacy of a once daily dose of adefovir dipivoxil in an open-label trial for the treatment of lamivudine-resistant HBV infection in HIV-1-infected patients...
  26. ncbi Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
    C Besson
    Hopital Necker, SC4 INSERM, CHU Pitie Salpetriere, Hopital Rothschild, Paris, France
    Blood 98:2339-44. 2001
    ..004). Therefore, the profile of ARL has changed since the era of HAART, with a lower incidence of systemic and brain ARL. The prognosis of systemic ARL has improved...
  27. ncbi Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy
    Y Benhamou
    Service d Hepato Gastroenterologie, Service de Pharmacie, Service de Virologie, Service de Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 34:283-7. 2001
    ....
  28. ncbi Fetal death as a result of placental immune reconstitution inflammatory syndrome
    F Caby
    Service des Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitie Salpetriere, Assistance Publique des Hopitaux de Paris AP HP, Paris, France
    J Infect 61:185-8. 2010
    ..This outcome remains undescribed and could represent an issue in resource-limited settings where HIV-pregnant patients are often severely immunodeficient and infected with opportunistic pathogens...
  29. ncbi Comparison of two genotypic algorithms to determine HIV-1 tropism
    C Soulie
    Department of Virology, Pitie Salpetriere Hospital, Pierre et Marie Curie Paris 6 University, 47 83 Bd de l Hopital, 75651 Paris Cedex 13, France
    HIV Med 9:1-5. 2008
    ..A comparison of the position-specific scoring matrices (PSSM) and Geno2pheno algorithms based on the V3 loop gp120 sequences and previously described to be correlated to the R5 or X4 phenotype was carried out...
  30. ncbi Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy
    Laurence Weiss
    Faculte de Medecine, Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Europeen Georges Pompidou, Paris, France
    PLoS ONE 5:e11659. 2010
    ..However, the insufficient increase in the proportion and/or the decrease in the absolute number of Tregs result in a failure to control immune activation following TI. TRIAL REGISTRATION: ClinicalTrials.gov NCT00118677...
  31. ncbi Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    J J Laurichesse
    Laboratoire de Recherche en Pathologie Infectieuse, Universite Paris 7, Paris, France
    HIV Med 11:239-44. 2010
    ..The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients...
  32. ncbi Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients
    S Lambert-Niclot
    INSERM U943, AP HP, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    HIV Med 11:666-9. 2010
    ..The objective of this study was to explore the virological response when combination atazanavir/ritonavir was administered to treatment-na?¨ve patients...
  33. ncbi A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Paris, France
    J Med Virol 82:1819-28. 2010
    ..A high PBMC HIV DNA level at TI was a strong predictor for more rapid treatment resumption...
  34. ncbi Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations
    M Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Clin Microbiol 49:2700-2. 2011
    ..0. In comparison with the Abbott RealTime assay, the mean difference that was 1.18 log(10) copies/ml is now zero. The discrepancies have disappeared...
  35. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  36. ncbi Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes
    M Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Clin Microbiol 47:1543-5. 2009
    ..The differences exceeded 0.5 log for about 20% of samples and 1 log for 3%, with higher values always from the Abbott assay in the latter cases...
  37. ncbi X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  38. ncbi Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial
    Xavier Duval
    Inserm CIC 007, Hopital Bichat, Paris, France
    Fundam Clin Pharmacol 23:491-500. 2009
    ....
  39. ncbi Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
    M A Valantin
    Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 65:556-61. 2010
    ..To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters...
  40. ncbi GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy
    P Bossi
    Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    HIV Med 5:352-9. 2004
    ..To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy in multiexperienced patients infected with HIV-1...
  41. ncbi P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors
    P Bossi
    Department of Virology, Pitie Salpetriere Hospital, 47 83 Bd de l Hopital, Paris, France
    HIV Med 4:67-71. 2003
    ..P-gps have been detected on peripheral CD4 blood cells in HIV-1-infected, but antiretroviral-naive patients...
  42. ncbi Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy
    M Jouan
    Department of Infectious Diseases, , Paris, France
    AIDS 15:23-31. 2001
    ..CONCLUSIONS: CMV retinitis maintenance therapy may be safely discontinued in patients with CD4 cell counts above 75 x 10(6) cells/l who have been taking HAART for at least 18 months...
  43. ncbi Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial
    J Ghosn
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 8:142-7. 2007
    ..88 log(10) HIV-1 RNA copies/mL. The magnitude of the reduction in viral load suggested that lower doses might still be effective while offering adequate safety during long-term use...
  44. ncbi Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus
    Aurelie Schnuriger
    INSERM, UMRS 945, Paris, France
    AIDS 23:2079-89. 2009
    ..To explore the parameters of specific immunity to hepatitis C virus (HCV) associated with virus clearance during acute HCV infection in HIV coinfection...
  45. ncbi How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
    ....
  46. ncbi Stability of HIV RNA in plasma specimens stored at different temperatures
    B Amellal
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:790-3. 2008
    ..Samples from remote areas are transported under suboptimal conditions. Here we evaluated HIV-1 RNA stability in plasma stored at different temperatures for 1 week...
  47. ncbi Pseudo-primary infection syndrome following discontinuation of antiretroviral therapy
    V Zeller
    Departement des Maladies Infectieuses et Tropicales, Hĵpital Pitié Salpêtrière, Paris, France
    Antivir Ther 6:191-3. 2001
    ..We report the case of a retroviral rebound syndrome associated with parotid gland enlargement in a chronically HIV-infected man...
  48. ncbi Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial
    Jean Luc Meynard
    Service des Maladies Infectieuses, Hopital Saint Antoine, Faculte de Medecine Pierre et Marie Curie, Paris, France
    J Antimicrob Chemother 65:2436-44. 2010
    ..We evaluated a monotherapy maintenance regimen with lopinavir/ritonavir versus continuing current combined antiretroviral treatment (cART) in HIV patients with suppressed plasma HIV-1 RNA...
  49. ncbi Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS
    L Baril
    Département de Maladies Infectieuses et de Santé Publique, Hopital de la Pitie Salpetriere, Paris, France
    AIDS 14:2593-6. 2000
    ..To assess the impact of highly active antiretroviral therapy (HAART) on the onset of first disseminated Mycobacterium avium complex (MAC) infection and first cytomegalovirus (CMV) disease episode in HIV-infected at-risk patients...
  50. ncbi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  51. ncbi Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification
    B Amellal
    Laboratoire de Virologie, hôpital La Pitié Salpêtrière, Paris, France
    HIV Med 8:396-400. 2007
    ..The aim of the study was to evaluate the use of dried plasma spots to determine HIV-1 RNA viral loads...
  52. ncbi T cell receptor gamma/delta+ lymphocyte subsets during HIV infection
    B Autran
    Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
    Clin Exp Immunol 75:206-10. 1989
    ..Altogether, those data suggest a conservation of the Ti-gamma A+ subset during HIV infection, contrasting with an increase of the delta-TcS1+, Ti-gamma A- fraction in some cases...
  53. ncbi HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  54. ncbi Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
    S Grabar
    Department of Public Health, Cochin Hospital, Paris, France
    HIV Med 9:246-56. 2008
    ....
  55. ncbi Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo
    G Haas
    Laboratory of Cellular and Tissue Immunology, Hospital Pitié Salpêtrière, Paris, France
    J Immunol 157:4212-21. 1996
    ..Therefore, a remarkable flexibility of the immune system allows constant adaptation of CTL to multiple HIV variants and thus elimination of HIV variant-producing cells in slow progressors...
  56. ncbi Quantitative analysis of human mitochondrial DNA using a real-time PCR assay
    K Gourlain
    Department of Virology, , Paris, France
    HIV Med 4:287-92. 2003
    ..The mtDNA changes in PBMCs were found to be fast as they fall off after 6 months' therapy, decreasing from 2.78 to 1.93 log copies/mL...
  57. ncbi Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
    L Michel
    INSERM U669, Paris, France
    J Viral Hepat 17:650-60. 2010
    ....
  58. ncbi Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study
    Jean Paul Viard
    Centre de Diagnostic et de Thérapeutique, Hotel Dieu, APHP, Paris, France
    AIDS 25:1305-15. 2011
    ..We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection...
  59. ncbi [Current clinical aspects of HIV/AIDS]
    V Zeller
    Service des Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitie Salpetriere, 47 83, Boulevard de l Hopital, F75013 Paris
    Presse Med 31:74-9. 2002
    ..At present, heterosexuality is the most frequent risk factor for HIV-infection (51%). Pneumocystis pneumonia remains the most common opportunistic illness in HIV-infected patients (28%)...
  60. ncbi Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy
    V Martinez
    Service de Dermatologie, Hopital Tarnier Cochin, AP HP, UPRES 1833, Université Paris V 89, rue d Assas, Paris 75006, France
    Br J Cancer 94:1000-6. 2006
    ..Suppression of HIV replication appears to be crucial to control KS. Non-PI-based regimens were equivalent to PI-based regimens as regards the clinical and virological outcome of antiretroviral-naive HIV-infected patients with KS...
  61. ncbi [Management of therapeutic failure in HIV-infected patients]
    P Bossi
    Service de Maladies Infectieuses et Tropicales, Hopital Pitie Salpetriere, 47 83, Bd de l Hopital, F 75651 Paris
    Presse Med 30:806-12. 2001
    ..The possible usefulness of regular drug assays for adjusting treatment doses in case of therapeutic escape remains to be assessed in prospective trials...
  62. ncbi Acute hepatitis C in HIV-infected men who have sex with men
    J Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    HIV Med 5:303-6. 2004
    ....
  63. ncbi Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients
    Deborah Hirt
    Service de Pharmacologie Clinique, AP HP, Hopital Cochin Saint Vincent de Paul, Universite Paris Descartes, Paris, France
    Br J Clin Pharmacol 65:548-57. 2008
    ..However, for MDR1 and CYP2C19 polymorphism, there have been contradictory studies, showing either no impact on nelfinavir concentration or modified concentrations which could influence virological response...
  64. ncbi Down-regulation of CD8+ T-cell expansions in patients with human immunodeficiency virus infection receiving highly active combination therapy
    G Gorochov
    Laboratoire d Immunologie Cellulaire, Hopital Pitie Salpetriere, Paris, France
    Blood 97:1787-95. 2001
    ..These data also suggested that autovaccination by the withdrawal of antiviral drugs would result in the selection and expansion of T-cell clones that were not necessarily dominant before the onset of treatment...
  65. ncbi Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection
    V Avettand-Fenoel
    Virology Department, , Paris, France
    J Clin Microbiol 44:2250-3. 2006
    ....
  66. ncbi Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes
    J Gabarre
    , , Paris, France
    Am J Med 111:704-11. 2001
    ....
  67. ncbi Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients
    I Kousignian
    INSERM, EMI 0214, Hopital Pitie Salpetriere, Paris, France
    Stat Med 22:1675-90. 2003
    ..Indeed, these patients' T cytotoxic responses were characterized by marked individual turnover and a gradual loss of multiple protein recognition over time, this loss accelerating as viral load increased...
  68. ncbi Tumor necrosis factor-alpha, microglia and astrocytes in AIDS dementia complex
    D Seilhean
    Laboratoire de Neuropathologie Raymond Escourolle, INSERM U360, Association Claude Bernard, Hopital de la Salpetriere, Paris, France
    Acta Neuropathol 93:508-17. 1997
    ....
  69. ncbi Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals
    A Schnuriger
    Department of Virology, , 83, , 75651 Paris Cedex 13, France
    J Clin Microbiol 44:1561-3. 2006
    ..Reduction of the long period of HCV seronegativity should improve the diagnosis of hepatitis C infection, especially in high-risk populations...
  70. ncbi Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
    J Antimicrob Chemother 62:797-808. 2008
    ..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
  71. ncbi Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, , Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003
    ..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
  72. ncbi Raltegravir with optimized background therapy for resistant HIV-1 infection
    Roy T Steigbigel
    State University of New York at Stony Brook, Stony Brook, USA
    N Engl J Med 359:339-54. 2008
    ..Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs...
  73. ncbi Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)
    Brigitte Autran
    UPMC Univ Paris 06, UMR_543, France
    AIDS 22:1313-22. 2008
    ..Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients...
  74. ncbi Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006
    Anne Derache
    UPMC Univ Paris 06, EA2387, 4 place Jussieu, F 75005 Paris, France
    J Antimicrob Chemother 62:456-63. 2008
    ..To describe HIV-1 variants circulating in Mali and to estimate the rate of transmission of HIV-1 drug resistance in 2006...
  75. ncbi Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort
    L Cuzin
    CISIH Hôpital Purpan, Toulouse, France
    HIV Clin Trials 9:147-51. 2008
    ..To assess virological efficacy of a ritonavir-boosted atazanavir (ATV/r)-containing regimen in patients with persistent viral replication despite HAART...
  76. ncbi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  77. ncbi Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir
    B Masquelier
    Laboratoire de Virologie, CHU de Bordeaux and EA 2968, Universite Victor Segalen, Bordeaux, France
    J Antimicrob Chemother 61:1362-8. 2008
    ..We developed clinically relevant genotypic scores for resistance to fosamprenavir/ritonavir in HIV-1 protease inhibitor (PI)-experienced patients...
  78. ncbi Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  79. ncbi Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology-EA2387, , Paris, France
    Antivir Ther 8:233-7. 2003
    ..CONCLUSION: Administration of IL-2 combined with HAART in HIV-1 infected-patients with advanced disease led to an increase of HIV-1 pro-viral DNA per million PBMC without virological failure or emergence of resistance...
  80. ncbi Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney
    N Engl J Med 359:355-65. 2008
    ....
  81. ncbi Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Adriano Lazzarin
    Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
    N Engl J Med 348:2186-95. 2003
    ....
  82. ncbi Primary infection with a lamivudine-resistant hepatitis B virus
    Vincent Thibault
    AIDS 16:131-3. 2002
  83. ncbi Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission
    Roland Tubiana
    AIDS 16:1083-4. 2002
  84. ncbi Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine
    Constance Delaugerre
    Department of Virology, , Paris, France
    Antimicrob Agents Chemother 46:1586-8. 2002
    ....
  85. ncbi M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
    Mounir Ait-Khaled
    International Clinical Virology Unit, UK
    AIDS 16:1686-9. 2002
    ..This suggests a direct effect of M184V on the reduced selection of TAMs. Lamivudine use was significantly associated with lower median fold resistance to zidovudine and stavudine...
  86. ncbi Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082
    Christine Katlama
    Service for Infectious and Tropical Diseases, Paris, France
    AIDS 16:2027-34. 2002
    ..CONCLUSIONS: Administration of interleukin-2 produces significant and sustained increase in CD4 cell counts in HAART-treated patients with persistent CD4 cell counts < 200 x 10(6) cells/l...
  87. ncbi Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients
    Jade Ghosn
    Department of Infectious Diseases, Inserm EO214, , Paris, France
    AIDS 17:209-14. 2003
    ..Tolerability of RTV/IDV was excellent. CONCLUSION: RTV/IDV (100/400 mg bid) yields significantly higher IDV plasma Cmin and lower IDV Cmax values relative to the standard IDV regimen, thereby improving both tolerability and efficacy...
  88. ncbi Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    AIDS 20:1141-50. 2006
    ..It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]...
  89. ncbi A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
    Remko van Leeuwen
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 17:987-99. 2003
    ..The triple nucleoside regimen utilized may be less likely to result in viral suppression to < 50 copies/ml, while the nevirapine-based regimen is associated with a lower increase in CD4 T lymphocytes...
  90. ncbi High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors
    Philippe Bossi
    AIDS 17:1108-10. 2003
  91. ncbi Changes in viral load in people with virological failure who remain on the same HAART regimen
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    Antivir Ther 8:127-36. 2003
    ..The time-course of selecting more replication-competent virus in patients with virological failure remains to be fully clarified...
  92. ncbi [Antiretroviral-induced toxiderma in HIV-infected patients]
    Eric Caumes
    Service des Maladies Infectieuses et Tropicales, , Paris (75
    Presse Med 32:1325-33. 2003
    ..The practical approach varies depending on the drug responsible, the clinical form of the toxiderma and the possible alternatives...
  93. ncbi Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases
    Isabelle Malet
    UPMC Universite Paris 06, Paris, France
    J Med Virol 80:754-61. 2008
    ..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials...
  94. ncbi Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
    Andrew Hill
    Liverpool University, Liverpool, UK
    Expert Opin Pharmacother 8:679-88. 2007
    ....
  95. ncbi A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial
    Zoe Fox
    Copenhagen HIV Programme (CHIP, Hvidovre University Hospital, Copenhagen, Denmark
    Antivir Ther 11:761-70. 2006
    ..Evolutionary distances from baseline were larger in viruses that did not contain M1841/V. More discernable benefits may be seen in patients with fewer drug options as potent cART may eclipse a benefit of M1841/V in COLATE...
  96. ncbi Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients
    Benedicte Roquebert
    Department of Virology, Pitié Salpêtrière Hospital and UPRES EA 2387, Universite Pierre et Marie Curie, Paris, France
    J Med Virol 79:207-11. 2007
    ..Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance...
  97. ncbi In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP-HP Pitie-Salpetriere Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  98. ncbi Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance
    Ana Canestri
    Department des Maladies Infectieuses, , Paris, France
    Antivir Ther 11:561-6. 2006
    ..CONCLUSION: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status...
  99. ncbi The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
    Joseph Eron
    Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Lancet 368:476-82. 2006
    ..INTERPRETATION: Fosamprenavir-ritonavir twice daily in treatment-naive patients provides similar antiviral efficacy, safety, tolerability, and emergence of resistance as lopinavir-ritonavir, each in combination with abacavir-lamivudine...